Acute Myeloid Leukemia Research Today is a free monthly online journal that collates and summarizes the latest research about Acute Myeloid Leukemia, including details on aml, symptoms, treatment, information.

Volume 2 (2005), Issue 7 (July)

1. Myeloperoxidase cytochemical negativity: an unexpected but intrinsic property of blasts of all phases of chronic myeloid leukemia.
   Ann Hematol. [Abstract] [Full-text]
2. Prognostic significance of del(20q) in patients with hematological malignancies.
   Cancer Genet Cytogenet, 160(2): 188-92. [Abstract] [Full-text]
3. Gain of 9p due to an unbalanced rearrangement der(9;18): a recurrent clonal abnormality in chronic myeloproliferative disorders.
   Cancer Genet Cytogenet, 160(2): 179-83. [Abstract] [Full-text]
4. Polysomy 8 defines a clinico-cytogenetic entity representing a subset of myeloid hematologic malignancies associated with a poor prognosis: report on a cohort of 12 patients and review of 105 published cases.
   Cancer Genet Cytogenet, 160(2): 97-119. [Abstract] [Full-text]
5. The fission yeast homolog of the human transcription factor EAP30 blocks meiotic spindle pole body amplification.
   Dev Cell, 9(1): 63-73. [Abstract] [Full-text]
6. Indole-3-carbinol suppresses NF-kappaB and IkappaBalpha kinase activation, causing inhibition of expression of NF-kappaB-regulated antiapoptotic and metastatic gene products and enhancement of apoptosis in myeloid and leukemia cells.
   Blood, 106(2): 641-9. [Abstract] [Full-text]
7. Internal tandem duplications of the FLT3 gene are present in leukemia stem cells.
   Blood, 106(2): 673-80. [Abstract] [Full-text]
8. Activation mutations of human c-KIT resistant to imatinib mesylate are sensitive to the tyrosine kinase inhibitor PKC412.
   Blood, 106(2): 721-4. [Abstract] [Full-text]
9. Analysis of FLT3 internal tandem duplication and D835 mutations in Chinese acute leukemia patients.
   Leuk Res. [Abstract] [Full-text]
10. Haunting appearance of bcr/abl fusion gene products in a patient with therapy related leukaemia.
    Leuk Res. [Abstract] [Full-text]
11. Loss of C/EBP alpha cell cycle control increases myeloid progenitor proliferation and transforms the neutrophil granulocyte lineage.
    J Exp Med, 202(1): 85-96. [Abstract] [Full-text]
12. Periconceptional vitamin useand leukemia risk in children with Down syndrome: a Children's Oncology Group study.
    Cancer, 104(2): 405-10. [Abstract] [Full-text]
13. Loss-of-function mutation of the AF9/MLLT3 gene in a girl with neuromotor development delay, cerebellar ataxia, and epilepsy.
    Hum Genet. [Abstract] [Full-text]
14. Immunologic purging of autologous peripheral blood stem cell products based on CD34 and CD133 expression can be effectively and safely applied in half of the acute myeloid leukemia patients.
    Clin Cancer Res, 11(13): 4793-801. [Abstract] [Full-text]
15. Bacteremia caused by an undescribed species of Janibacter.
    J Clin Microbiol, 43(7): 3564-6. [Abstract] [Full-text]
16. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    N Engl J Med, 353(1): 33-45. [Abstract] [Full-text]
17. A retroviral library genetic screen identifies IRF-2 as an inhibitor of N-ras-induced growth suppression in leukemic cells.
    Oncogene. [Abstract] [Full-text]
18. Beginning treatment for pediatric acute myeloid leukemia: the family connection.
    Issues Compr Pediatr Nurs, 28(2): 97-114. [Abstract] [Full-text]
19. Decreased expression of CCAAT/enhancer binding protein zeta (C/EBPzeta) in patients with different myeloid diseases.
    Leuk Res. [Abstract] [Full-text]
20. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias.
    Exp Mol Pathol, 79(1): 39-41. [Abstract] [Full-text]
21. Expression of cyclin A1 and cell cycle proteins in hematopoietic cells and acute myeloid leukemia and links to patient outcome.
    Eur J Haematol, 75(2): 106-15. [Abstract] [Full-text]
22. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia.
    Cancer Chemother Pharmacol. [Abstract] [Full-text]
23. Acute myeloid leukemia: therapeutic impact of epigenetic drugs.
    Int J Biochem Cell Biol, 37(9): 1752-62. [Abstract] [Full-text]
24. Safety evaluation of DT388IL3, a diphtheria toxin/interleukin 3 fusion protein, in the cynomolgus monkey.
    Cancer Immunol Immunother, 54(8): 799-806. [Abstract] [Full-text]
25. Autologous or allogeneic stem cell transplantation as post-remission therapy in refractory or relapsed acute myeloid leukemia after highly intensive chemotherapy.
    Leuk Lymphoma, 46(7): 1007-16. [Abstract] [Full-text]
26. Clinical implications of angiogenic factors in patients with acute or chronic leukemia: Hepatocyte growth factor levels have prognostic impact, especially in patients with acute myeloid leukemia.
    Leuk Lymphoma, 46(6): 885-91. [Abstract] [Full-text]
27. Outcome of patients less than 55 years of age with high-risk acute leukemia who did not have an human leukocyte antigen-identical related donor: a long-term study of 97 consecutive patients.
    Leuk Lymphoma, 46(6): 841-9. [Abstract] [Full-text]
28. Evaluation of cytotoxicity by flow cytometric drug sensitivity assay in childhood T-cell acute lymphoblastic leukemia.
    Leuk Lymphoma, 46(6): 833-41. [Abstract] [Full-text]
29. The use of liposomal daunorubicin (DaunoXome) in acute myeloid leukemia.
    Leuk Lymphoma, 46(6): 795-802. [Abstract] [Full-text]
30. Ante-mortem diagnosis of localized invasive esophageal aspergillosis in a patient with acute myeloid leukemia.
    Leuk Lymphoma, 46(4): 603-5. [Abstract] [Full-text]
31. Predictive value of karyotype on outcome of autotransplants for acute myeloid leukemia in second remission.
    Leuk Lymphoma, 46(4): 525-31. [Abstract] [Full-text]
32. NK-cell neoplasms in Japan.
    Hematology, 10(3): 237-45. [Abstract] [Full-text]
33. Heat shock proteins and acute leukemias.
    Hematology, 10(3): 225-35. [Abstract] [Full-text]
34. Soluble VEGF/sFLt1 ratio is an independent predictor of AML patient out come.
    Hematology, 10(2): 131-4. [Abstract] [Full-text]
35. Human T-lymphotropic virus type I infection and idiopathic thrombocytopnic purpura.
    Hematology, 10(2): 95-9. [Abstract] [Full-text]
36. Apoptosis and immaturity in acute myeloid leukemia.
    Hematology, 10(1): 25-34. [Abstract] [Full-text]
37. The integrity of the charged pocket in the BTB/POZ domain is essential for the phenotype induced by the leukemia-associated t(11;17) fusion protein PLZF/RARalpha.
    Cancer Res, 65(14): 6080-8. [Abstract] [Full-text]
38. Is it appropriate to offer allogeneic hematopoietic stem cell transplantation to patients with primary refractory acute myeloid leukemia?
    Bone Marrow Transplant, 36(3): 183-91. [Abstract] [Full-text]
39. Nuclear phospholipase C: involvement in signal transduction.
    Prog Lipid Res, 44(4): 185-206. [Abstract] [Full-text]
40. Control of advanced and refractory acute myelogenous leukaemia with sirolimus-based non-myeloablative allogeneic stem cell transplantation.
    Br J Haematol, 130(2): 256-64. [Abstract] [Full-text]
41. Case report: successful interdisciplinary treatment of cerebrally disseminated invasive pulmonal aspergillosis in a child with acute myeloid leukemia.
    J Pediatr Surg, 40(7): 1191-4. [Abstract] [Full-text]
42. Simultaneous detection of NPM1 and FLT3-ITD mutations by capillary electrophoresis in acute myeloid leukemia.
    Leukemia, 19(8): 1479-82. [Abstract] [Full-text]
43. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis.
    Leukemia, 19(8): 1345-9. [Abstract] [Full-text]
44. Antiangiogenic treatment with endostatin inhibits progression of AML in vivo.
    Leukemia, 19(8): 1312-7. [Abstract] [Full-text]
45. The novel triterpenoid CDDO-Me suppresses MAPK pathways and promotes p38 activation in acute myeloid leukemia cells.
    Leukemia, 19(8): 1350-4. [Abstract] [Full-text]
46. Prognostic impact of RT-PCR-based quantification of WT1 gene expression during MRD monitoring of acute myeloid leukemia.
    Leukemia, 19(8): 1416-23. [Abstract] [Full-text]
47. AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
    Leukemia, 19(8): 1355-60. [Abstract] [Full-text]
48. Common 4q24 deletion in four cases of hematopoietic malignancy: early stem cell involvement?
    Leukemia, 19(8): 1411-5. [Abstract] [Full-text]
49. Mutations in the receptor tyrosine kinase pathway are associated with clinical outcome in patients with acute myeloblastic leukemia harboring t(8;21)(q22;q22).
    Leukemia, 19(8): 1361-6. [Abstract] [Full-text]
50. Expression and methylation status of the FHIT gene in acute myeloid leukemia and myelodysplastic syndrome.
    Leukemia, 19(8): 1367-75. [Abstract] [Full-text]
51. Essential role for the p110delta isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia.
    Blood, 106(3): 1063-6. [Abstract] [Full-text]
52. Egr-1 abrogates the block imparted by c-Myc on terminal M1 myeloid differentiation.
    Blood, 106(3): 871-8. [Abstract] [Full-text]
53. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF.
    Blood, 106(3): 803-11. [Abstract] [Full-text]
54. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance.
    Blood, 106(3): 899-902. [Abstract] [Full-text]
55. Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia.
    Blood, 106(3): 938-45. [Abstract] [Full-text]
56. JAK2 mutation 1849G >T is rare in acute leukemias but can be found in CMML, Philadelphia-chromosome negative CML and megakaryocytic leukemia.
    Blood. [Abstract] [Full-text]
57. Busulfan/melphalan/antithymocyte globulin followed by unrelated donor cord blood transplantation for treatment of infant leukemia and leukemia in young children: the Cord Blood Transplantation study (COBLT) experience.
    Biol Blood Marrow Transplant, 11(8): 637-46. [Abstract] [Full-text]
58. Low blast count myeloid disorders with Auer rods: a clinicopathologic analysis of 9 cases.
    Am J Clin Pathol, 124(2): 191-8. [Abstract] [Full-text]
59. Expression of heat-shock proteins is associated with major adverse prognostic factors in acute myeloid leukemia.
    Leuk Res, 29(9): 1049-58. [Abstract] [Full-text]
60. Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.
    Leuk Res, 29(9): 1003-7. [Abstract] [Full-text]
61. Outcome of patients with acute myelogenous leukemia after second salvage therapy.
    Cancer, 104(3): 547-54. [Abstract] [Full-text]
62. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia.
    Ann Oncol, 16(8): 1366-73. [Abstract] [Full-text]
63. AML bearing the translocation t(11;17)(q23;q21): involvement of MLL and a region close to RARA, with no differentiation response to retinoic acid.
    Ann Hematol. [Abstract] [Full-text]
64. 5-Aza-2'-deoxycytidine (decitabine) can relieve p21WAF1 repression in human acute myeloid leukemia by a mechanism involving release of histone deacetylase 1 (HDAC1) without requiring p21WAF1 promoter demethylation.
    Leuk Res. [Abstract] [Full-text]
65. Phosphorylation of AML1/RUNX1 regulates its degradation and nuclear matrix association.
    Mol Cancer Res, 3(7): 391-401. [Abstract] [Full-text]
66. The rationale for deltanoids in therapy for myeloid leukemia: Role of KSR-MAPK-C/EBP pathway.
    J Steroid Biochem Mol Biol. [Abstract] [Full-text]
67. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure.
    Antimicrob Agents Chemother, 49(8): 3550-3. [Abstract] [Full-text]
68. Runx1 deficiency predisposes mice to T-lymphoblastic lymphoma.
    Blood. [Abstract] [Full-text]
69. In vitro profiling of the sensitivity of pediatric leukemia cells to Tipifarnib (ZarnestraTM): Identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
    Blood. [Abstract] [Full-text]
70. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics - interaction with other gene mutations.
    Blood. [Abstract] [Full-text]

© 2004-2012 Acute Myeloid Leukemia Research Today. All Rights Reserved.